January 2020 Volume 16, Issue 1

Volume 16, Issue 1 | January 2020
January 2020
In this Issue
Preclinical

Meeting a new mechanism
Samumed publishes unique mechanism of action for SM08502
Targeting tough tumors
Femtogenix payload platform has favorable toxicity profile
A model replacement?
Heart-on-a-Chip technology predicts preclinical systolic, diastolic in-vivo observations for cardiac drug candidate
Knowing the score
New application helps authors, publishers address heightened reproducibility and transparency standards
Immunic presents data on IMU-856 at Crohn’s and colitis conference
IMU-856 might address a root cause of inflammatory bowel disease without impairing immune systemClinical Trials

Phase 3 on the horizon
Oramed's oral insulin candidate shows efficacy in Phase 2b diabetes trial
Triple combination study shows promise
BioLineRx’s combination regimen leads to improved disease control in pancreatic cancer
ADVM-022 success is no OPTICal illusion
Adverum’s wet AMD candidate helps maintain vision in Phase 1 trial
Resistance to Alzheimer’s is not futile
Troriluzole successfully advances past interim futility analysis in pivotal Phase 2/3 study
Antibody vs. Alzheimer’s disease
Alector announces Phase 1 data on AL002 at 12th annual CTAD meetingDiscovery

Collaboration “DUBbed” a success
Mission and AbbVie deal reaches milestone as partnership continues
Making waves with macrophages
NTU Singapore scientists discover new key to promote insulin production in pre-diabetes patients
Onward and upward
Three companies will enter 2020 with support to launch new growth
Models for seeing things more clearly
Two new cell models for ocular drug discovery could reduce the need for animal testing
Streamlining CRISPR gene-editing workflows
Individual sgRNA and library collections expand Edit-R gene-editing platformEditor's Focus

Editor’s Focus: Double helix, double bind
Of all the areas where 'just because you can doesn't mean you should' ought to be a leading tenet, genomics is at the top of the list. The promise of gene editing must be partnered with caution regarding the ways it could be mishandled; we need to decide now which lines shouldn't be crossed, rather than backtracking after someone steps over them.Special Reports

Special Report on Gene Therapy: Finding the pathfinders
Researchers move beyond cut-and-paste to address genetic disordersFeature

SOT/ToxExpo 2020 Show Preview: A taste of toxicology
The ‘best in toxicological research’ makes its way to AnaheimResearch & Development

Aggravating atherosclerosis
Study of T cells sheds light on cardiovascular events
Open Targets finds differences in immune disease DNA
With strong financial backing from Open Targets, a battery of scientists is working to identify specific variations in DNA that correspond with different immune diseases
Akoya finds $50M more in financing
Funding will support continued commercialization of Akoya’s spatial biology platforms
Oral therapy for hemophilia
Bayer enters into collaboration with Children’s Hospital of Philadelphia on novel small-molecule drugsContract Services

Drugging the undruggable
Cresset Discovery Services contracted by PhoreMost to work on oncology protein target
Dose CMO industry performing strongly
This despite challenges of increasingly complex drug production, says GlobalDataDiagnostics

Stepping up against sepsis
Companies ink agreement to develop rapid, point-of-care solution for diagnosing bloodstream infections
Cologuard mechanism tested for liver cancer
Test that has proven useful for non-invasive colorectal cancer screening leads to new possibilities
Duo for diagnostics
Startup company Breakthrough Diagnostics performs clinical testing of LymPro test for Alzheimer’s diseaseBusiness & Government Policy

End of the road
Illumina and Pacific Biosciences announce termination of merger agreement
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Expedeon and Abcam close transaction
With deal sealed, Expedeon changes name and shifts to DNA manufacturing and enzymes for diagnostics
Fast-tracking the regulation submission process
Yseop and Litera partner up to help life-sciences companies
Patent Docs: More on patent-ineligibility from the Federal Circuit
The Federal Circuit continuse to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinionCommentary

Out of order: For the better
Science is elusive and ever shifting, refusing to come into focus, and that is both its curse and its blessing
Case study: Managing informatics challenges across distributed drug discovery projects
Collaboration between drug discovery groups from different sites, organizations and companies has become much more common, and distributing research can have profound advantages even as managing the process poses unique challenges

Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe